RBC
REGN icon

Roble Belko & Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Roble Belko & Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-91
Closed -$31K – 326
2018
Q2 		$31K Sell
91
-65
-42% -$20.3K 0.01% 135
2018
Q1 		$54K Buy
156
+91
+140% +$31.7K 0.02% 120
2017
Q4 		$24K Buy
+65
New +$26.3K 0.01% 156
2017
Q2 		– Sell
-9
Closed -$3K – 340
2017
Q1 		$3K Hold
9
– – ﹤0.01% 293
2016
Q4 		$3K Buy
+9
New +$3.42K ﹤0.01% 312

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Roble Belko & Company's REGN Position: Q3 2018 in Review

Roble Belko & Company sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 91 shares — an estimated $31K sold.

Roble Belko & Company first reported a position in REGN in Q4 2016 and held it in 5 quarters. The position peaked at $54K in Q1 2018. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

  • Roble Belko & Company reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Roble Belko & Company sold 91 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $31K.
  • Roble Belko & Company first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • Roble Belko & Company's Regeneron Pharmaceuticals position peaked at $54K in Q1 2018.
  • 644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Roble Belko & Company's 13F filing for Q3 2018, filed 14 Nov 2018.